Conditions: Advanced Non-squamous Non-Small Cell Lung Cancer
Keywords: Non-squamous Non-Small Cell Lung Cancer Bevacizumab Ambulatory Blood Pressure Monitoring
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.

Detailed description:
Carboplatin and pemetrexed are FDA approved chemotherapy agents for patients with advanced non squamous non small cell lung cancer. Bevacizumab is also FDA approved in lung cancer , and the combination of all three drugs is promising. The doctors directing this research want to learn how to better personalize drug dosing of bevacizumab by identifying people who could safely take a higher dose of the drug.

Arms:
arm 1: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses arm 2: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses

Interventions: intervention 1: Pemetrexed intervention 2: Carboplatin intervention 3: Bevacizumab 7.5 mg/kg intervention 4: Bevacizumab 15 mg/kg
Intervention descriptions: intervention 1: Pemetrexed 500 mg/m\^2 intravenously over 10 minutes intervention 2: Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes intervention 3: Bevacizumab at 7.5 mg/kg intravenously over 90 minutes intervention 4: Bevacizumab at 15 mg/kg intravenously over 90 minutes

Protocol document: